Coral Laboratories Ltd
Incorporated in 1994 and headquartered in Mumbai – India Coral Laboratories Ltd is into the Manufacturing of Pharmaceutical formulations. The company manufactures Generic – Branded, Herbal Medicines, etc. in the product categories of Non-Sterile, Sterile, Nutraceuticals, Otc + Lifestyle, and it exports its products mainly to Ethiopia and other parts of the world.[1]
- Market Cap ₹ 283 Cr.
- Current Price ₹ 794
- High / Low ₹ 999 / 345
- Stock P/E 12.2
- Book Value ₹ 570
- Dividend Yield 0.25 %
- ROCE 12.6 %
- ROE 9.58 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of -1.69% over past five years.
- Company has a low return on equity of 6.55% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
42 | 51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 111 | |
34 | 41 | 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 85 | |
Operating Profit | 8 | 10 | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 |
OPM % | 18% | 20% | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% |
1 | 1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 7 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 8 | 10 | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 31 |
Tax % | 20% | 21% | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | |
6 | 8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 23 | |
EPS in Rs | 16.88 | 22.03 | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 64.75 |
Dividend Payout % | 9% | 9% | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | -2% |
3 Years: | -5% |
TTM: | 52% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 9% |
3 Years: | 6% |
TTM: | 198% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 42% |
3 Years: | 43% |
1 Year: | 82% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 7% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 40 | 47 | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 200 |
1 | 0 | 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 0 | |
14 | 10 | 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 28 | |
Total Liabilities | 58 | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 232 |
21 | 20 | 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
Investments | 1 | 1 | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 63 |
36 | 40 | 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 145 | |
Total Assets | 58 | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 232 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 0 | 5 | 11 | 13 | -1 | -4 | 1 | 6 | 13 | -5 | |
0 | 1 | -0 | -3 | -10 | -13 | 3 | -2 | -0 | -6 | -3 | 1 | |
0 | 0 | -0 | -0 | 0 | -3 | -1 | 4 | 0 | 0 | -6 | 0 | |
Net Cash Flow | 1 | 2 | -0 | 2 | 1 | -2 | 1 | -2 | 1 | 0 | 4 | -4 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 93 | 109 | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 |
Inventory Days | 124 | 97 | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 |
Days Payable | 97 | 61 | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 |
Cash Conversion Cycle | 120 | 145 | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 |
Working Capital Days | 143 | 159 | 202 | 181 | 172 | 168 | 177 | 241 | 202 | 251 | 221 | 183 |
ROCE % | 19% | 21% | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% |
Documents
Announcements
-
Submission Of Limited Review Report Missed Inadvertently In Financial Result Submitted On 14Th November, 2024
26 Nov - Submission of standalone financial results for Q2 2024.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Publication of standalone unaudited financial results.
-
Disclosure Under Reg 23(9) Of SEBI (LODR) Regulations, 2015
14 Nov - Disclosure of related party transactions for H1 2024.
- Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30, 2024, As Per Regulation 33 Under SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 14 Nov
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14, 2024, Pursuant To Regulation 30 (Read With Part A Of Schedule III) The SEBI (LODR) Regulations, 2015 ("Listing Regulations")
14 Nov - Board approved unaudited financial results for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio: [1]
The four important product categories include:
Non-Sterile: This comprises Capsules, Tablets, Dry syrup, etc. in Antibiotics/Anti-bacterial, Anti-fungal, Gastro-Intestinal Drugs, etc.
Sterile: This category includes Injectables, Eye Drops, Ear Drops, Nasal Sprays, and large volume Parenteral.
Nutraceuticals: The company provides a wide range of nutraceutical products such as dietary supplements, herbal / phytochemicals, multi-vitamins, and nutrients.
OTC+Lifestyle: The company provides products in the range of Female Hygiene, Contraceptives, Medical Devices, Skin Care, Infant & Child Care products, and Herbal products.